Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Table 1 Baseline and clinical characteristics collected from medical records

Factor	n(%)/x ̅±S / M, Q25-Q75
Age	51.130 ± 9.565
BMI	23.83, 22.03–26.17
PLD dose intensity	31.20, 28.99–34.22
ECOG 1 Score	5 (1.1)
Hypertension disease	45 (9.8)
Diabetes	32 (6.9)
Cholecystitis	25 (5.4)
History of gallstones	21 (4.6)
Good peripheral blood circulation	339 (73.5)
Excessive sweat excretion	83 (18.0)
Allergic to the first infusion	23 (5.0)
Viral hepatitis	31 (6.7)
neoadjuvant treatment	128 (27.8)
ER+	307 (66.6)
PR+	266 (57.7)
HER-2+	112 (24.3)
KI-67 high expression	301 (65.3)
Baseline ALT	15, 12–21
Baseline AST	19, 17–23
Baseline GGT	19, 14–26
Baseline TBIL	13, 10–16.35
Baseline MONO	0.37, 0.305–0.45
Baseline NLR	1.75, 1.345–2.365
Baseline PLR	132, 108–170.5
Baseline CA153	9.2, 7–13.7
Baseline CEA	1.64, 1–2.5

KI-67 high expression: Ki67 > 20% was considered high expression
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG eastern cooperative oncology group, ER estrogen receptor, GGT γ-glutamyl transpeptidase, IQR interquartile range, HER2 human epidermalgrowth factor receptor-2, Ki-67 antigen identified by monoclonal antibody Ki-67, MSHFS moderate to severe hand-foot syndrome, MONO monocytes, NLR neutrophil-lymphocyte ratio, NMHFS none and mild hand-foot syndrome, PLR platelet-lymphocyte ratio, PR progesterone receptor, TBIL total bilirubin

ISSN: 1471-2407